Colospan Announces FDA Approval of IDE for Intraluminal Bypass Device – an Alternative approach to Diverting Stoma
Colospan which develops novel solutions for colorectal surgery, announced today that the United States Food and Drug Administration (FDA) has approved the company’s investigational device exemption (IDE) application. With this IDE approval in hand, the company will launch its pivotal study for CG-100, a temporary Intraluminal Bypass Device, designed to reduce diverting stoma rates in patients undergoing gastrointestinal resection procedures.
Colospan Completes $7.7M Equity Financing Round – Reports Successful Results of Clinical Trial
Colospan Ltd., a company developing innovative solutions for colorectal surgery, announced it has raised $7.7 million in a financing round led by Triventures and a strategic medical devices company. Existing investors, AMIT (The Alfred Mann Institute at the Technion), Docor BV and Anatomy Medical Technology Fund also participated in the round.
Colospan Selected to Present its Colorectal Surgical Device at the Life Science Intelligence Summit in Silicon Valley
Colospan Ltd., a company developing revolutionary solutions for colorectal surgery, announced that was selected to be a presenter the Emerging Medical Technologies (EMT) Summit on November 9-11, 2016, located at the heart of the medical technology development and investment hub in California’s Silicon Valley.
Colospan Completes 20th Patient Recruitment for Clinical Trial
Colospan Ltd., a company developing revolutionary solutions for colorectal surgery, announced that it has recruited 20 patients for its clinical trial, thus completing the number of required patients for this trial.
AMIT Invests $0.5M in Colospan
Colospan Ltd., a company developing revolutionary solutions for colorectal surgery, announced that AMIT (The Alfred Mann Institute at the Technion) has invested $0.5M in the company.
Colospan Recruits $2M in its Second Funding Round
Colospan Ltd., a company developing revolutionary solutions for colorectal surgery, announced that it completed the 2nd round of funding, totaling $2M, from VI Ventures and the existing investors.
